The transaction values Ignite at nearly $150m and will create a standalone public company focused on precision oncology.
Aditxt plans to separate its Ignite Proteomics subsidiary through a business combination valuing the unit at approximately $150m. The deal will establish Ignite as an independent public company, with shares expected to list on the New York Stock Exchange pending approvals and closing conditions.
Aditxt acquired Ignite to advance health innovation platforms, particularly in precision oncology. The spin-off aims to provide Ignite with a dedicated structure and enhanced access to growth capital, accelerating commercialization and clinical development.
Upon completion, Ignite will operate under a new holding company, with Aditxt’s acquisition corporation and Ignite becoming wholly owned subsidiaries. The transaction reflects Aditxt’s strategy to unlock value in its portfolio assets.